‘Intended copies’ of innovator biologics currently in use for the treatment of rheumatoid arthritis (not subjected to current European Medicines Agency/Food and Drug Administration standards for biosimilarity at the time of approval)
| Reference product | Manufacturer | ‘Intended copy’ agent | Marketed locations |
|---|---|---|---|
| Rituximab | Dr Reddy's Laboratories (India) | Reditux | Bolivia, Chile, India and Peru |
| Rituximab | Probiomed (Mexico) | Kikuzubam | Bolivia, Chile, Mexico, and Peru |
| Etanercept | Shanghai CP Goujian Pharmaceutical Co (China) | Etanar | Colombia |
| Etanercept | Shanghai CP Goujian Pharmaceutical Co (China) | Yisaipu | China |
Adapted by permission from Macmillan Publishers Ltd: (Nature reviews rheumatology),17 copyright (2012).